Vocational education company Adtalem Global Education (NYSE:ATGE) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 12.9% year on year to $466.1 million. The company’s full-year revenue guidance of $1.77 billion at the midpoint came in 0.9% above analysts’ estimates. Its non-GAAP profit of $1.92 per share was 16.2% above analysts’ consensus estimates. Is now the time to buy Adtalem? Find out in our full research report. Adtalem (ATGE) Q1 CY2025 Highlights: Revenue: $466.1 million vs analyst estimates of $446.4 million (12.9% year-on-year growth, 4.4% beat) Adjusted EPS: $1.92 vs analyst estimates of $1.65 (16.2% beat) Adjusted EBITDA: $127.8 million vs analyst estimates of $111.2 million (27.4% margin, 14.9% beat) The company lifted its revenue guidance for the full year to $1.77 billion at the midpoint from $1.75 billion, a 1.3% increase Management raised its full-year Adjusted EPS guidance to $6.50 at the midpoint, a 4.8% increase Operating Margin: 19.4%, in line with the same quarter last year Free Cash Flow Margin: 52%, up from 34.2% in the same quarter last year Market Capitalization: $4.28 billion Company Overview Formerly known as DeVry Education Group, Adtalem Global Education (NYSE:ATGE) is a global provider of workforce solutions and educational services. Sales Growth A company’s long-term performance is an indicator of its overall quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Over the last five years, Adtalem grew its sales at a 10.5% annual rate. Although this growth is acceptable on an absolute basis, it fell short of our standards for the consumer discretionary sector, which enjoys a number of secular tailwinds.Adtalem Quarterly Revenue Long-term growth is the most important, but within consumer discretionary, product cycles are short and revenue can be hit-driven due to rapidly changing trends and consumer preferences. Adtalem’s annualized revenue growth of 9.7% over the last two years aligns with its five-year trend, suggesting its demand was consistently weak.Adtalem Year-On-Year Revenue Growth This quarter, Adtalem reported year-on-year revenue growth of 12.9%, and its $466.1 million of revenue exceeded Wall Street’s estimates by 4.4%. Looking ahead, sell-side analysts expect revenue to grow 4.7% over the next 12 months, a deceleration versus the last two years. This projection is underwhelming and indicates its products and services will face some demand challenges. Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories. Story Continues Operating Margin Adtalem’s operating margin has risen over the last 12 months and averaged 18% over the last two years. On top of that, its profitability was top-notch for a consumer discretionary business, showing it’s an well-run company with an efficient cost structure.Adtalem Trailing 12-Month Operating Margin (GAAP) This quarter, Adtalem generated an operating profit margin of 19.4%, in line with the same quarter last year. This indicates the company’s overall cost structure has been relatively stable. Earnings Per Share We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable. Adtalem’s EPS grew at a spectacular 21.9% compounded annual growth rate over the last five years, higher than its 10.5% annualized revenue growth. However, this alone doesn’t tell us much about its business quality because its operating margin didn’t expand.Adtalem Trailing 12-Month EPS (Non-GAAP) In Q1, Adtalem reported EPS at $1.92, up from $1.50 in the same quarter last year. This print easily cleared analysts’ estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects Adtalem’s full-year EPS of $6.39 to grow 8.2%. Key Takeaways from Adtalem’s Q1 Results We enjoyed seeing Adtalem beat analysts’ EBITDA expectations this quarter. We were also glad its revenue outperformed Wall Street’s estimates. Overall, we think this was a solid quarter with some key areas of upside. The stock traded up 2.5% to $119 immediately after reporting. Adtalem had an encouraging quarter, but one earnings result doesn’t necessarily make the stock a buy. Let’s see if this is a good investment. The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it’s free. View Comments
Adtalem (NYSE:ATGE) Surprises With Strong Q1, Full-Year Outlook Slightly Exceeds Expectations
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...